KMS Pharma provides contract pharmaceutical formulation development services spanning drug-excipient compatibility, prototype screening, process engineering, and Module 3 CTD regulatory documentation.
When evaluating a pharmaceutical formulation development company in India, research directors and formulation scientists must examine how early laboratory batch data will hold up under high-speed commercial production, stability testing under Zone IVb climatic conditions, and bioequivalence expectations. A formulation that performs reliably at a 1 kg laboratory scale must be engineered from day one to deliver identical release profiles at 100 kg commercial batch sizes.
Leading Pharmaceutical Formulation Development Company in India
Formulation development transforms the physical and chemical properties of an Active Pharmaceutical Ingredient (API) into a bioavailable, shelf-stable, and reproducible therapeutic product. In India’s highly competitive pharmaceutical landscape, success depends on systematic preformulation, intelligent excipient selection, and rigorous process design.
KMS Pharma delivers structured development strategies for both conventional generics and complex, differentiated delivery systems. By embedding Quality by Design (QbD) and Design of Experiments (DoE) into early prototype evaluation, our research teams isolate critical formulation variables, establish safe processing ranges, and minimize unexpected scale-up failures.
Every programme begins by defining a Target Product Profile (TPP) and evaluating available patent and compendial constraints. We map formulation risks alongside bioequivalence considerations, analytical testing requirements, and packaging barrier demands to ensure your commercial product meets international pharmacopeial standards.
Target Product Profile (TPP) Definition: Establish clear physicochemical, release, and packaging specifications before bench trials commence.
Solid-State API Characterisation: Evaluate polymorphism, particle size distribution (PSD), hygroscopicity, and drug-excipient compatibility.
Science-Based Risk Assessment: Identify high-impact formulation and process variables using ICH Q8, Q9, and Q10 risk principles.
Data-Driven Scale-Up: Generate pilot-scale operational parameters to derisk future commercial validation and CDMO technology transfer.
9 Solid Oral Technologies
Comprehensive process technologies supporting immediate-release, sustained-release, multilayer tablets, and encapsulated pellets.
15 Sterile Delivery Formats
Formulation capabilities spanning terminally sterilised injections, lyophilised cakes, aseptic pre-filled syringes, and ophthalmic solutions.
QbD & DoE Methodology
Structured factorial design matrices that establish robust design spaces and support regulatory submissions across global agencies.
Contract Formulation Development Services in India
Pharmaceutical companies in India and international drug developers frequently require specialised contract R&D partners to handle complex dosage forms, patent workaround designs, and rapid lifecycle extensions. KMS Pharma operates as a true extension of your internal scientific team.
Our laboratories handle formulations across every development tier—from exploratory prototype batches for proof-of-concept studies to pivotal exhibit batches destined for regulatory dossier submissions.
Generic Formulation R&D
Reverse engineering of reference listed drugs (RLDs), non-infringing formulation development, and bioequivalence-aligned in vitro dissolution matching.
Poorly Soluble Compounds
Enabling technologies for BCS Class II and IV molecules using solid dispersions, spray drying, micronisation, and self-emulsifying systems (SEDDS).
Method Development & Validation
On-site HPLC, GC, dissolution apparatus, and stability chambers providing rapid assay, related substances, and degradation profile feedback.
Module 3 CTD Compilation
Drafting comprehensive pharmaceutical development reports (PDR), batch manufacturing records (BMR), and validation protocols ready for eCTD filing.
Manufacturing Site Transfer
Seamless execution of technology transfer protocols, on-site scientist supervision, and scale-up troubleshooting at commercial Indian manufacturing sites.
Phase I/II Clinical Batches
Formulation support for exploratory investigational new drugs (INDs), clinical blinding, and pilot clinical trial batch manufacturing coordination.
The Pharmaceutical Formulation Process: From Molecule to Scale-Up
A successful formulation programme follows a disciplined, step-by-step pathway. Each phase generates empirical evidence that informs the next stage, eliminating costly surprises when moving from laboratory benches to pilot machinery.
Patent, literature & regulatory landscape review
In-depth analysis of innovator patents, intellectual property claims, regulatory guidelines, compendial monographs, and therapeutic requirements to establish non-infringing pathways.
Quality Target Product Profile (QTPP) & CQAs
Defining target critical quality attributes including release kinetics, dosage strength, assay limits, stability targets, and patient usability criteria.
Preformulation & excipient compatibility studies
Thermal analysis (DSC), moisture sorption profiling, forced degradation under stress conditions, and screening excipients for chemical and physical compatibility.
Prototype formulation & DoE screening
Developing multiple prototype formulations using systematic experimental matrices to assess binder concentrations, disintegration times, and process feasibility.
Process development & boundary parameter testing
Establishing operating design spaces across granulation fluid addition, drying temperatures, compression forces, and coating spray rates.
Stress & formal ICH stability testing
Evaluating prototype batches under accelerated (40°C/75% RH) and real-time conditions (Zone II and Zone IVb) to determine packaging configuration and shelf-life stability.
Pilot-scale batch manufacturing & tech transfer package
Running pilot trials on production-equivalent equipment to generate comprehensive batch documentation and technology transfer dossiers for commercial execution.
Oral Solid Formulation Development in India
Oral solid dosage forms—including tablets, capsules, and multiparticulates—remain the bedrock of the global pharmaceutical market. Selecting the correct processing route depends on the drug substance’s bulk density, flowability, moisture sensitivity, compressibility, and dissolution targets.
Rather than applying generic direct compression formulas, KMS Pharma evaluates wet granulation, dry granulation, roller compaction, and pelletisation to engineer a robust commercial process.
Wet & Dry Granulation
High-shear wet granulation, fluid bed top-spray granulation, and roller compaction for moisture-sensitive and heat-labile active ingredients.
Extrusion & Spheronisation
Fuji Paudal extrusion systems for producing uniform multiparticulates and spheroids suitable for controlled-release and site-specific targeting.
Wurster & Auto-Coating
Aqueous and solvent-based film coating, enteric coating for gastric protection, and Wurster bottom-spray coating of sugar spheres and pellets.
Rotary Compression & Multilayer
Tooling evaluation (D and B tooling), tablet breaking force optimisation, capping prevention, and bilayer tablet development for fixed-dose combinations.
Hard & Soft Gelatin Filling
Automated capsule filling for dry powders, granules, pellets, mini-tablets, and combination fills within hard gelatin or HPMC shells.
Micronisation & Air-Jet Milling
Precision particle-size reduction to increase surface area, accelerate dissolution rates, and optimize bioequivalence for poorly soluble molecules.
Oral Liquid and Topical Semi-Solid Formulation Development
Oral liquids and topical semi-solids address critical therapeutic needs for paediatric, geriatric, and dermatological healthcare. Suspensions, solutions, drops, hydrogels, and medicated creams require meticulous evaluation of physical stability, rheology, and container-closure compatibility.
Our formulation laboratories develop stable liquid matrices, solve difficult solubility barriers, and execute switch programmes—such as converting existing solid oral products into palatable oral liquids with matched pharmacokinetic exposure.
Oral Solutions & Syrups: pH-solubility profiling, non-sugar vehicle design, co-solvent optimisation, and flavour masking for paediatric acceptability.
Oral Suspensions & Reconstitutables: Flocculation kinetics, sedimentation profiling, redispersibility testing, and viscosity modifier selection for dry syrups.
Topical Creams & Ointments: Emulsion droplet size distribution, phase inversion temperatures, penetration enhancer screening, and dermal spreadability.
Dermatological Gels & Lotions: Polymer hydration kinetics, clarity control, preservative efficacy testing (PET), and microbial limit testing.
Sterile Injectable & Ophthalmic Formulation Development
Sterile formulations require zero-tolerance standards across bioburden control, particulate contamination, and container-closure integrity. The development strategy must balance API stability with the chosen sterilisation method—whether terminal sterilisation or aseptic processing.
KMS Pharma’s sterile portfolio covers 15 delivery formats, spanning conventional aqueous injectables to lyophilised complex cakes and targeted ophthalmic suspensions.
Aqueous & Non-Aqueous Injections
Formulation of ready-to-use small-volume parenterals (SVP) and large-volume parenterals (LVP) using validated solubilisation and buffering systems.
Freeze-Dried Formulations
Lyophilisation cycle design, collapse temperature profiling, bulking agent optimisation, and reconstitution kinetics for unstable hydrolytic molecules.
Sterile Eye Drops & Emulsions
Osmolality adjustment, buffer capacity control, ocular tolerance, and viscosity enhancement for sustained contact time without blurring.
Nanosuspensions & Microemulsions
Sub-micron particle size distribution achieved through high-pressure homogenisation for intravenous and intramuscular depot delivery.
Pre-Filled Syringes (PFS) & Cartridges
Evaluation of siliconisation levels, extractables/leachables, plunger glide force, and break-loose force over real-time storage.
Liposomes & Microspheres
Phospholipid selection, encapsulation efficiency optimisation, and polymer degradation kinetics for sustained-release parenteral depots.
Formulation Development for Complex Molecules & Oncology
Specialised therapeutic molecules introduce significant formulation and occupational safety challenges. Difficult solubility, chemical instability, narrow therapeutic windows, and containment requirements demand specialised development frameworks.
KMS Pharma designs development programmes tailored to the distinctive degradation pathways and handling demands of complex drug entities.
Carbapenems & β-Lactams
Stabilisation strategies and process controls for imipenem, ertapenem, and meropenem sterile powder formulations.
Anti-Cancer Formulations
Development of injectable oncology formulations, including taxane solutions, lyophilised cytotoxic cakes, and nanoparticle dispersions.
Peptides & Proteins
Mitigating aggregation, deamidation, and oxidation through targeted surfactant screening, cryoprotectants, and pH-stabilised aqueous vehicles.
Endocrine & Hormone Therapies
Uniform low-dose blend development and barrier packaging solutions to protect low-concentration actives from environmental degradation.
505(b)(2) Value-Added Products
Reformulation to improve bioavailability, accelerate onset of action, improve tolerability, or introduce new administration routes.
NCE Formulation Support
Enabling early formulation development to deliver stable preclinical and early clinical Phase I trial supplies for novel drug candidates.
Advanced Drug Delivery Platforms (NDDS)
When conventional delivery methods fail to provide adequate patient compliance, bioavailability, or patent distinctiveness, novel drug delivery systems offer a strategic advantage.
Orally Disintegrating Films (ODF)
Ultra-thin polymer matrices that dissolve rapidly in saliva without water intake, providing rapid mucosal absorption and ideal compliance for dysphagic patients.
Orally Disintegrating Wafers (ODW)
Freeze-dried or rapidly porous matrix wafers designed to disintegrate in seconds, engineered for fragile active ingredients requiring quick sublingual entry.
Self-Emulsifying Drug Delivery Systems (SEDDS / SNEDDS)
Isotropic mixtures of oils, surfactants, and co-solvents that form fine oil-in-water micro/nano emulsions upon contact with gastrointestinal fluid, drastically improving bioavailability.
Targeted & Pulsatile Multiparticulates
Enteric and chronotherapeutic polymer coats applied to multiparticulates for targeted colon delivery or dual-phase immediate/sustained release profiles.
State-of-the-Art Formulation Equipment & Pilot Facility
Reproducible formulation science relies on process equipment that mirrors commercial equipment geometry and mechanics. KMS Pharma’s laboratories feature pilot-scale systems that enable precise parameter mapping prior to commercial transfer.
ACG Fluid Bed Processor
Equipped with interchangeable top-spray granulation and Wurster bottom-spray coating inserts for multiparticulates and pellets.
Roll Compactor
Pilot roller compactor with adjustable roll pressure, feed screw speed, and gap control for evaluating dry compaction without solvents.
Fuji Paudal Extruder & Spheroniser
Industry-standard extrusion-spheronisation equipment for producing uniform, dense pellets with narrow size distributions.
Cadmach & Karnavati Rotary Presses
17-station Cadmach and 10-station Karnavati rotary tablet presses supporting standard B and D tooling configurations.
Neocota Perforated Coating Pan
Automated coating system with peristaltic spray control, air volume modulation, and exhaust temperature tracking for tablet coating.
MF 300 Capsule Machine
Precision capsule filling equipment capable of filling powder blends, pellets, and mini-tablets into sizes 000 through 5 capsules.
Air-Jet Mill & Multi Mill
Pneumatic micronisation and multi-mill systems with variable screen sizes to achieve desired particle-size distributions.
GEA Niro Soavi Panda Plus
High-pressure homogeniser operating up to 2,000 bar for generating sub-micron emulsions, liposomes, and nanosuspensions.
Octagonal & Double-Cone Blenders
Interchangeable 3 L, 5 L, and 7 L stainless steel blenders with internal baffle options for blend uniformity optimization.
Quality by Design (QbD) & Design of Experiments (DoE)
Modern regulatory authorities like the US FDA and European Medicines Agency expect pharmaceutical submissions to demonstrate deep product and process understanding. KMS Pharma integrates QbD into every formulation project, moving away from empirical trial-and-error.
Through Design of Experiments (DoE), our scientists assess multi-factor interactions—such as binder concentration, spray rate, inlet temperature, and compression force—to establish a proven design space where quality attributes remain consistent.
QTPP & CQA Identification: Pinpointing critical parameters that directly impact dissolution, stability, and bioavailability.
Initial Risk Assessment: Utilising Ishikawa (fishbone) diagrams and Failure Mode and Effects Analysis (FMEA) to identify high-risk variables.
Statistical Factorial Design: Applying full factorial, fractional factorial, and response surface methodologies (RSM).
Proven Acceptable Ranges (PAR): Documenting operational operating limits that ensure product compliance under real commercial conditions.
Formulation Stability Studies & CDMO Technology Transfer
A successful laboratory batch is meaningless if the product degrades over time or cannot be scaled up reliably on commercial production lines. Our formulation scientists execute stress testing and formal ICH stability assessments alongside comprehensive technology transfer protocols.
We generate development stability data to guide primary packaging selection (PVC/PVDC blisters, Alu-Alu, HDPE bottles) and verify formulation resilience against temperature and humidity challenges.
Accelerated & Stress Stability Studies
Testing prototypes at 40°C/75% RH, photostability chambers, and thermal cycling to detect early impurity degradation and physical changes.
In Vitro Bioequivalence Dissolution Profiling
Comparative dissolution profiling in multiple media (pH 1.2, 4.5, 6.8) and f1/f2 statistical analysis to ensure bioequivalence against the innovator product.
Technology Transfer Dossier (TTD) Creation
Comprehensive documentation encompassing critical process parameters (CPPs), equipment operating settings, in-process testing specifications, and master formula cards.
Commercial Plant Scale-Up Supervision
On-site technical support during exhibit batch execution and commercial process validation at your designated CDMO facility.
Why Global Pharma Chooses India for Formulation Development
India has evolved from a generic volume manufacturing powerhouse into a premier global hub for sophisticated pharmaceutical formulation research and development. International drug sponsors and domestic enterprises leverage India's scientific infrastructure for significant strategic advantages:
World-Class R&D Talent
Access to seasoned formulation scientists, analytical chemists, and regulatory specialists trained across global pharmaceutical pharmacopeias.
Optimised Development Costs
Achieve comprehensive formulation development, analytical method validation, and stability testing at a fraction of Western Europe or US development costs.
Domestic API & Excipient Supply
Direct proximity to the world’s largest cluster of US FDA-approved API manufacturing sites, drastically shortening raw material sourcing cycles.
Global Inspection Familiarity
Indian formulation development workflows are engineered to satisfy the rigorous data integrity and validation requirements of CDSCO, US FDA, EMA, and WHO.
Agile Project Turnaround
Flexible laboratory scheduling and dedicated project management ensure prototype iterations and stability readouts progress without institutional delays.
Seamless Manufacturing Linkages
Direct technology transfer pathways into hundreds of GMP-certified commercial manufacturing facilities throughout India's major pharmaceutical clusters.
How to Choose a Formulation Development Partner in India
Selecting the right contract formulation partner dictates whether your drug candidate reaches commercial launch on schedule or gets bogged down by regulatory queries and manufacturing failures.
Before signing a formulation development contract, evaluate prospective partners using these fundamental scientific criteria:
Dosage Form Specific Equipment: Verify that the laboratory operates the specific process equipment required for your molecule (e.g., Wurster columns for pellets, micro-fluidizers for nano-emulsions, or lyophilizers for injectables).
Integrated Analytical Capabilities: Ensure analytical method development, related substances testing, and stability chambers are managed on-site rather than subcontracted to third parties.
Proven QbD Methodology: Confirm the team uses formal statistical experimental design (DoE) rather than empirical trial-and-error formulation attempts.
Regulatory Dossier Experience: Ask for proof of prior Module 3 CTD submissions prepared for US FDA (ANDAs/505(b)(2)), European National/DCP filings, or CDSCO approvals.
Scale-Up & Tech Transfer Track Record: Confirm that the contract research organization provides on-site technical support during plant-scale exhibit and commercial validation batches.
Discuss Your Formulation Development Project
Whether you are planning a generic bioequivalent formulation, developing a differentiated drug delivery platform, or seeking technology transfer support in India, KMS Pharma's scientific team is ready to assist. Contact our programme leads to discuss your molecule, target product profile, and development timelines.
Discuss Your Requirements